# Evidence of fructose metabolism in colorectal cancer

## TL;DR

This study shows that fructose metabolism plays a role in colorectal cancer, suggesting new treatment strategies targeting cancer cell metabolism.

## Contribution

The study provides evidence for fructose metabolism's role in CRC progression through targeted metabolomics and omics approaches.

## Key findings

- Elevated serum D-Fructose and L-Lactic acid levels suggest increased glycolytic activity in CRC patients.
- Fructose metabolism appears to be involved in CRC progression via the polyol pathway.
- The findings highlight potential therapeutic targets related to the Warburg effect in CRC.

## Abstract

Colorectal cancer (CRC) represents a significant global health burden, contributing significantly to cancer-related mortality. The underlying genetic and metabolic underpinnings of CRC remain incompletely understood. In this study, we conducted a comprehensive investigation into metabolic perturbations in 29 CRC patients utilizing targeted omics approaches, compared to public databases. Additionally, we examined serum and tissue samples from 12 patients, with and without preoperative glucose challenge, using targeted metabolomics to investigate glucose and fructose metabolism. Notably, elevated levels of serum D-Fructose and L-Lactic acid following glucose administration indicate augmented glycolytic activity and polyol pathway-mediated glucose conversion (to fructose). Despite variations in tumor responses, our results underscore the potential significance of fructose metabolism in CRC progression, shedding light on therapeutic avenues targeting the Warburg effect. This research lays a solid foundation for future translational research into metabolic interventions in CRC treatment and enhances our understanding of cancer-related metabolic reprogramming.